<DOC>
	<DOCNO>NCT03034460</DOCNO>
	<brief_summary>Exploratory , multi-center , randomise , investigator-blinded , vehicle control study use intra-individual comparison involve subject acne vulgaris face evaluate efficacy CD5024 1 % cream 6-week treatment period compare vehicle .</brief_summary>
	<brief_title>Efficacy Safety CD5024 1 % Acne Vulgaris</brief_title>
	<detailed_description>Study drug application perform daily , 5 day week 6 week</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . The subject male female age 18 35 year old screening visit . 2 . The subject medical diagnosis acne vulgaris : 2.1 least 20 ( twenty ) inflammatory lesion maximum 100 ( one hundred ) noninflammatory lesion ( nose exclude lesion count ) Baseline 2.2 symmetry lesion : No twice many acne lesion one side compare side Baseline 3 . If subject female childbearing potential , must agree use effective contraceptive method duration study 1 . The subject underlie known disease surgical medical condition , opinion investigator might interfere interpretation study result put subject risk ( e.g. , dermatological disease affect treatment area , dermatitis , eczema , etc. , uncontrolled chronic serious disease would normally prevent participation clinical study , cancer , leukemia severe hepatic impairment ) , ( Screening ) . 2 . The subject acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc . ) , nodulo cystic acne , acne require systemic treatment . 3 . The subject know suspected allergy sensitivities component study drug ( see Investigator 's Brochure/Product label ) . 4 . The subject male beard facial hair , would interfere clinical evaluation clinical procedure ( Screening Baseline ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>